Medical device demand is set to benefit from Japan's aging population, with potential for margins to remain robust even if revenue growth moderates. The company's Price-To-Earnings ratio of 10.6x stands out as a clear discount to both the industry average of 15.4x and the peer average of 19.8x, positioning Japan Lifeline as a defensive value play in the medical devices sector with strong operational execution.
Cyborg Score Rationale
Japan Lifeline posted earnings growth of 22% over the past twelve months with net profit margin improving to 16.7% from 14.6%. The company has more cash and short-term investments (18B JPY) than debt (6B JPY). Strong fundamentals and financial health are offset by modest forward growth guidance.
Top Insights
Trading at 10.6x P/E, significantly below industry average of 15.4x and peer average of 19.8x, suggesting undervaluation
Earnings growth of 22% over past twelve months well above five-year average of 16.9% per year
Outlook for earnings and revenue growth has slowed, falling behind market averages
Net profit margin of 16.7% positions company among margin leaders in its peer group
Named Competitors
Cardiac Rhythm Management Systems — Global leaders in pacemakers and defibrillator systems
Electrophysiology Products — Specialists in ablation catheters and EP systems
Vascular Intervention Products — Japanese competitors in endovascular and intervention space
Recent Developments
(Oct 2025) Earnings growth of 22% YoY with net margin expansion to 16.7%
(Jun 2024) Nippon IBR issued updated sponsored research report highlighting business strategies and investor relations focus
(Jan 2024) Analyst price target increased 15.31% to 1,479 JPY
Open the full interactive Japan Lifeline Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.